FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2025年7月2日 I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00874 說明 香港聯交所上市 H 股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 219,900,000 RMB 1 RMB 219,900,000 增加 / 減少 (-) RMB 本月底結存 219,900,000 RMB 1 RMB 219,900,000 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600332 | 說明 | | 於上海證券交易所 （「上交所」）上市之A股 | | | | | | | | 法定/ ...

廣州白雲山醫藥集團股份有限公司 董事會 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 關連交易進展公告 向白雲山生物增資 茲提述廣州白雲山醫藥集團股份有限公司（「本公司」）日期為2025年5月28日之公告（「該公告」）,內容 有關向白雲山生物增資之關連交易。除另有界定外，本公告所用詞彙與該公告所界定者具有相同涵 義。 董事會欣然宣佈於2025年6月30日，本公司與廣藥創投基金、廣州老字號基金、廣藥產投基金、國資 併購基金、拜迪生物及白雲山生物訂立了增資協議，增資協議於同日正式生效。增資協議的主要條 款並無任何變更。增資協議的主要條款及本次增資詳情載於該公告。 本次增資完成後，本公司於白雲山生物的直接及間接持股比例維持不變，仍為50.00%。白雲山生物 仍為本公司之附屬公司，其財務業績繼續納入本公司之合併報表。 中國廣州，2025年6月30日 於本公告日，本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生，及獨立非執 ...

Group 1 - The board of directors of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. held its 26th meeting of the 9th session on June 23, 2025, with all 9 directors participating and voting [1][2] - The meeting approved the proposal to add new members to the specialized committees of the board, with a unanimous vote of 9 in favor, 0 against, and 0 abstentions [1] - The newly appointed members to the specialized committees include Mr. Li Xiaojun, Mr. Cheng Hongjin, and Mr. Tang Heping, effective from the date of the board's approval until the end of the current board's term [1][2] Group 2 - The composition of the Strategic Development and Investment Committee now includes Mr. Li Xiaojun as the chairperson and members Mr. Li Hong, Mr. Chen Yajin, and Ms. Sun Baoqing [1] - The Nomination and Remuneration Committee is chaired by Mr. Huang Min, with members including Mr. Chen Yajin, Ms. Sun Baoqing, and the newly added Mr. Cheng Hongjin [2] - The Budget Committee is chaired by Mr. Chen Yajin, with members including Ms. Cheng Ning, Mr. Huang Min, Mr. Huang Longde, and the newly added Mr. Tang Heping [2]

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. has approved its 2024 annual equity distribution plan during the shareholders' meeting held on June 3, 2025, emphasizing its commitment to shareholder returns [1] Summary by Relevant Sections Equity Distribution Plan - The equity distribution plan includes a record date of June 18, 2025, and the ex-dividend date and cash dividend payment date are both set for June 19, 2025 [1] - The distribution is targeted at A-share shareholders registered with China Securities Depository and Clearing Corporation Limited in Shanghai as of the close of trading on the record date [1] Taxation Details - Individual shareholders and securities investment funds holding shares for over one year are exempt from personal income tax, while those holding for one month to one year are taxed at a rate of 10%, and those holding for less than one month are taxed at 20% [1] - Qualified Foreign Institutional Investors (QFII) and investors through the Shanghai-Hong Kong Stock Connect are subject to a 10% tax rate [1] Shareholder Engagement - The dividend plan reflects the company's focus on returning value to shareholders and aligns with relevant tax policy requirements [1] - Investors are advised to pay attention to the record date and tax treatment details to ensure the smooth realization of their rights [1]

Core Viewpoint - Baiyunshan has received approval for the registration of Tadalafil tablets, positioning it as a successor to its existing product, Jin Ge (Sildenafil) [1][3]. Group 1: Product Overview - Tadalafil is a PDE5 inhibitor similar to Sildenafil, primarily used for treating erectile dysfunction (ED) [1][3]. - Tadalafil has advantages over Sildenafil, including lower dosage, longer half-life, and less impact from high-fat meals and alcohol [3]. Group 2: Market Dynamics - The domestic market for Tadalafil has not performed as well as Sildenafil, facing intense competition and a dual market structure of hospital and retail sales [3][4]. - In 2024, Tadalafil's sales in public hospitals were only RMB 186 million, indicating a limited market size [7]. - The introduction of centralized procurement policies has compressed the market ceiling for Tadalafil in hospitals [4]. Group 3: Competitive Landscape - In 2024, Tadalafil's total sales in hospitals were RMB 142 million, with the original drug, Cialis, holding a 30.14% market share, while generic competitors have gained significant volume [7][11]. - The retail market for Tadalafil is much larger, with total sales of approximately RMB 2.906 billion in 2024, split between offline and online pharmacies [14]. - The online retail market is highly fragmented, with various brands competing for market share [20]. Group 4: Challenges and Future Outlook - Baiyunshan faces challenges in establishing Tadalafil as a blockbuster product due to the competitive landscape and lack of first-mover advantage [23]. - The company is also exploring other male health medications, such as Dapoxetine, but the overall market for these products is limited [24]. - Jin Ge's sales and revenue have declined in 2024, indicating potential saturation in its market [24][25].

Major Events - JiuTai Rural Commercial Bank (06122) plans to sell 78.51% stake in HuanShan HuiMin Village Bank for 40.4 million yuan [1] - Vanke Enterprises (02202) intends to receive a loan of up to 3 billion yuan from its major shareholder, Shenzhen Metro Group [1] - China Gas Holdings (08246) signed a memorandum of understanding with the Lao Ministry of Industry and Commerce to explore cooperation in developing fuel and natural gas supply networks in Laos [1] - Miniso Group (09896) is conducting a preliminary assessment on the potential spin-off listing of its trendy toy business operated under the "TOP TOY" brand [1] - Baiyunshan Pharmaceutical (00874) subsidiary received approval from the National Medical Products Administration for the drug registration certificate of Tadalafil tablets (2.5mg, 5mg) [1] - Huaxing Capital Holdings (01911) portfolio company Circle successfully listed on the New York Stock Exchange, marking the first IPO milestone in the global stablecoin sector [1] - China National Nuclear Corporation (01763) plans to initiate its first irradiation station cooperation project in Peru [1] Operating Performance - Yuexiu Property (00123) reported a cumulative contract sales amount of approximately 50.7 billion yuan in the first five months, an increase of about 26.5% year-on-year [1] - China Overseas Land & Investment (00688) recorded a cumulative property sales amount of approximately 90.4 billion yuan in the first five months, a decrease of 11.1% year-on-year [1] - Shimao Group (00813) reported a cumulative contract sales total of 11.2 billion yuan in the first five months, a decrease of 18.71% year-on-year [1] - Zhongliang Holdings (02772) achieved a cumulative contract sales amount of approximately 5.37 billion yuan in the first five months, a decrease of 33.38% year-on-year [1] - GAC Group (02238) experienced a year-on-year decline in May's automobile production by 8.16% and a sales drop of 24.80% [1] - Poly Property Group (00119) achieved a contract sales amount of approximately 21.8 billion yuan in the first five months, an increase of 3.81% year-on-year [1] - New天绿色能源 (00956) completed a power generation volume of approximately 7.29 million megawatt-hours in the first five months, an increase of 10.86% year-on-year [1]

Group 1 - The company has received the drug registration certificate for Tadalafil tablets (2.5mg, 5mg) from the National Medical Products Administration [1][2] - Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor primarily used for treating erectile dysfunction (ED) [2] - The original manufacturer of Tadalafil is Eli Lilly, which received approvals in the EU and the US in November 2002 and November 2003, respectively, and in China in December 2004 [2] Group 2 - The company submitted the drug registration application for Tadalafil on January 2, 2024, and received acceptance on January 24, 2024 [2] - In 2024, the sales figures for Tadalafil tablets in Chinese public hospitals, urban pharmacies, and online pharmacies were approximately RMB 185.73 million, RMB 1.294 billion, and RMB 1.61182 billion, respectively [2] - The company has invested approximately RMB 2.54 million and RMB 4.30 million in the R&D of 2.5mg and 5mg Tadalafil tablets, respectively [3] Group 3 - The approval of Tadalafil tablets enhances the company's product offerings in the male medication sector, potentially increasing its market competitiveness [3] - The company plans to commence production in accordance with relevant requirements and market demand [3]

Core Viewpoint - The company has received the drug registration certificate for Tadalafil tablets (2.5mg, 5mg), enhancing its product offerings in the male medication market and improving its competitive position in this sector [1][2]. Drug Information - The drug's generic name is Tadalafil, with active ingredients being Tadalafil in tablet form, available in specifications of 2.5mg and 5mg [1]. - The registration classification is categorized as a Class 4 chemical drug, with certificate numbers 2025S01530 and 2025S01529 [1]. - The drug is approved for use in treating erectile dysfunction (ED) and was originally developed by Eli Lilly, receiving approvals in the EU and the US in 2002 and 2003, respectively, and in China in 2004 [1]. Market Context - The registration application for Tadalafil tablets was accepted on January 24, 2024, and the approval is valid until May 26, 2030 [1]. - Major competitors in the domestic market include Guangdong Dongyangguang Pharmaceutical Co., Ltd., Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd., and Lefusi Health Industry Co., Ltd., with sales figures of RMB 185.73 million, RMB 1.294 billion, and RMB 1.61182 billion, respectively [1]. - The company has invested approximately RMB 2.5401 million and RMB 4.2976 million in the R&D of Tadalafil tablets (2.5mg and 5mg) [1]. Impact on the Company - The acquisition of the drug registration certificate will diversify the product range of the company's male medication offerings, thereby enhancing its competitiveness in the male medication market [2]. - The company plans to commence production in accordance with regulatory requirements and market demand [2].

证券代码：600332 证券简称：白云山 公告编号：2025－048 规格：2.5mg、5mg 注册分类：化学药品 4 类 证书编号：2025S01530、2025S01529 广州白云山医药集团股份有限公司 关于分公司收到药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 分公司广州白云山医药集团股份有限公司白云山制药总厂（以下简称 "白云山制药总厂"）收到国家药品监督管理局核准签发关于他达拉 非片（2.5mg、5mg）的《药品注册证书》。现将相关情况公告如下： 一、药品的基本情况 药品通用名称：他达拉非片 主要成份：他达拉非 剂型：片剂 药品注册标准编号：YBH10982025 上市许可持有人：（1）名称：广州白云山医药集团股份有限公 司白云山制药总厂；（2）地址：广州市白云区同和街云祥路 88 号 生产企业：（1）名称：广州白云山医药集团股份有限公司白云 山制药总厂；（2）地址：广州市白云区同和街云祥路 88 号 受理号：CYHS2400338、 ...

Core Insights - The health food industry is experiencing significant growth driven by innovation, with the FFI2025 Food Formula Innovation Forum highlighting future trends in functional foods [1] - Guangzhou Baiyunshan Weiyi Industrial Co., Ltd. showcased its star product, the Dendrobium officinale probiotic solid beverage, which won the "2025 Innovation Exploration Award" through expert evaluation and consumer voting [1][3] Group 1 - The Dendrobium officinale probiotic solid beverage combines traditional medicine and modern probiotic technology, meeting diverse health needs of modern consumers [3] - The expert panel praised the product for its innovative formula that integrates traditional wisdom with modern scientific logic, setting a benchmark in the probiotic market [3] Group 2 - Dendrobium officinale has a long history of medicinal use, documented in ancient texts like "Compendium of Materia Medica," and modern pharmacological studies confirm its health benefits due to over 30 active substances [5] - The company selected the AB21 composite probiotics, which include Lactobacillus plantarum and Lactococcus lactis, achieving a perfect blend of traditional medicine and modern probiotic technology [5] Group 3 - The forum reinforced the "scientific formula" concept of the Dendrobium officinale probiotics, reflecting the company's commitment to quality and consumer health, while promoting a healthy lifestyle [7] - As a key member of the Guangzhou Pharmaceutical Group's health industry, the company leverages its billion-level industrial ecosystem to meet consumer demands with a range of popular health products [7] - The company aims to continue its focus on "technology and traditional Chinese medicine," investing in the modernization and scientific research of traditional health culture to provide innovative and practical health solutions [7]